• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Convalescent Plasma Donors Needed for COVID-19

April 22, 2020

Hospitals and blood collection centers are working with the US Government collaboratively to collect convalescent plasma from patients who have recovered from COVID-19. Convalescent plasma has been used since the 1890s to treat many viral and bacterial infections including other coronavirus outbreaks (i.e., Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome). Researchers hope that the convalescent plasma will be rich in SARS-CoV-2 antibodies and lessen the severity or shorten the length of illness for COVID-19 patients, as limited data from two small studies in China suggest. The US FDA is urging recovered COVID-19 patients to donate plasma, and they recently established a new web page to help guide potential donors through the process. Potential donors must have had a confirmed SARS-CoV-2 infection, be symptom free for at least two weeks, undergo additional testing to ensure they are negative for the virus, and meet standard donor eligibility requirements. Demand for convalescent plasma for COVID-19 is currently much higher than supply as there are currently no proven therapies or prophylactic vaccines. To date, over 1600 sites and 2,140 physicians have registered with the Mayo Clinic and FDA to help administer convalescent plasma to over 2000 patients with severe or life-threatening COVID-19, and 600 patients have already been transfused. Clinical trials to examine the safety and efficacy of anti-SARS-CoV-2 plasma are also underway.

References:

  1. Bloch EM, Shoham S, Casadevall A, Sachais BS, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation 2020
  2. Duan K, Liu B, Li C, Zhang H, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. PNAS 2020
  3. Shen C, Wang Z, Zhao F, Yang Y, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020
  4. Expanded access to convalescent plasma for the treatment of patients with COVID-19
  5. COVIDPlasma.org
  6. FDA Press Announcement April 16, 2020. Coronavirus (COVID-19) update: FDA encourages recovered patients to donate plasma for development of blood related therapies

Filed Under

  • Blood Donation
  • Coagulation & Plasma Transfusion
  • News
  • Platelet Transfusion

Recommended

  • Hypoxic Storage Helps to Preserve Red Blood Cells

  • Platelet Rich Plasma Injections Are Not Beneficial for Acute Hamstring Injuries

  • Restrictive Transfusion Strategies Safe for Extremely Low Birth-Weight Infants

Show Comments

Reader Interactions

Comments

  1. Max Doleh says

    May 7, 2020 at 1:50 pm

    If a blood bank or a hospital would like to have potential donors that recovered from COVID-19 submit their info and self-qualify, we can help. This is free for many!

    https://www.perfeqta.io/convalescent-plasma

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley